{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:48:52Z","timestamp":1759837732309},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases (NIAID)","doi-asserted-by":"crossref","award":["R43AI075747"],"award-info":[{"award-number":["R43AI075747"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.vaccine.2010.10.039","type":"journal-article","created":{"date-parts":[[2010,10,30]],"date-time":"2010-10-30T08:21:12Z","timestamp":1288426872000},"page":"289-303","source":"Crossref","is-referenced-by-count":21,"title":["Impact of ST-246\u00ae on ACAM2000\u2122 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice"],"prefix":"10.1016","volume":"29","author":[{"given":"Aklile","family":"Berhanu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie","family":"Mosier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin F.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis E.","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"Grosenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.10.039_bib0005","series-title":"Smallpox and its Eradication","author":"Fenner","year":"1988"},{"issue":"June","key":"10.1016\/j.vaccine.2010.10.039_bib0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.0105-2896.2006.00392.x","article-title":"Immunity and immunological memory following smallpox vaccination","volume":"211","author":"Amanna","year":"2006","journal-title":"Immunol Rev"},{"issue":"November (Suppl 4)","key":"10.1016\/j.vaccine.2010.10.039_bib0015","doi-asserted-by":"crossref","first-page":"D73","DOI":"10.1016\/j.vaccine.2009.07.103","article-title":"Smallpox vaccines for biodefense","volume":"27","author":"Kennedy","year":"2009","journal-title":"Vaccine"},{"issue":"October (4)","key":"10.1016\/j.vaccine.2010.10.039_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"122","author":"Lane","year":"1970","journal-title":"J Infect Dis"},{"issue":"April (17)","key":"10.1016\/j.vaccine.2010.10.039_bib0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review, part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"February (RR-4)","key":"10.1016\/j.vaccine.2010.10.039_bib0035","first-page":"1","article-title":"Smallpox vaccination and adverse reactions. Guidance for cliniciens","volume":"52","author":"Cono","year":"2003","journal-title":"MMWR Recomm Rep"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0040","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1086\/374244","article-title":"Progressive vaccinia","volume":"36","author":"Bray","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"August","key":"10.1016\/j.vaccine.2010.10.039_bib0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1542\/peds.26.2.176","article-title":"Studies smallpox and complications of smallpox vaccination","volume":"26","author":"Kempe","year":"1960","journal-title":"Pediatrics"},{"issue":"June (RR-10)","key":"10.1016\/j.vaccine.2010.10.039_bib0050","first-page":"1","article-title":"Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001","volume":"50","author":"Rotz","year":"2001","journal-title":"MMWR Recomm Rep"},{"issue":"March\u2013April (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0055","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper","year":"2002","journal-title":"Eff Clin Pract"},{"issue":"October (20)","key":"10.1016\/j.vaccine.2010.10.039_bib0060","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2010.10.039_bib0065","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/135965350701200802","article-title":"Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures","volume":"12","author":"Duraffour","year":"2007","journal-title":"Antivir Ther"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2010.10.039_bib0070","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/AAC.01044-08","article-title":"In vitro efficacy of ST-246 against smallpox and monkeypox","volume":"53","author":"Smith","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"April (1)","key":"10.1016\/j.vaccine.2010.10.039_bib0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1743-422X-6-44","article-title":"et al Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis","volume":"6","author":"Chen","year":"2009","journal-title":"Virol J"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0080","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.00879-06","article-title":"Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2010.10.039_bib0085","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00678-09","article-title":"ST-246 inhibits in vivo poxvirus dissemination. Virus shedding, and systemic disease manifestation","volume":"53","author":"Berhanu","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"April (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0090","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Non- human primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.10.039_bib0095","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification","volume":"53","author":"Jordan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0100","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1073\/pnas.0912134107","article-title":"Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice","volume":"107","author":"Grosenbach","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.10.039_bib0105","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.01303-07","article-title":"Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor","volume":"52","author":"Jordan","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"April (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0110","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/AAC.01689-09","article-title":"Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246(R) following repeat oral dosing in healthy adult subjects","volume":"54","author":"Jordan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"February (7)","key":"10.1016\/j.vaccine.2010.10.039_bib0115","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.vaccine.2007.11.095","article-title":"Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination","volume":"26","author":"Grosenbach","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.10.039_bib0120","series-title":"7th ASM Biodefense Emerging Dis Res Meet, abstr190 (H)","article-title":"Impact of concurrent ST-246 administration on ACAM2000 vaccine efficacy in cynomolgus macaques","author":"Silvera","year":"2009"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2010.10.039_bib0125","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/587668","article-title":"Severe eczema vaccinatum in a household contact of a smallpox vaccinee","volume":"46","author":"Vora","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2010.10.039_bib0130","first-page":"532","article-title":"Progressive Vaccinia in a Military Smallpox Vaccinee \u2014 United States, 2009","volume":"58","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"43","key":"10.1016\/j.vaccine.2010.10.039_bib0135","first-page":"1204","article-title":"Human Vaccinia Infection After Contact with a Raccoon Rabies Vaccine Bait \u2014 Pennsylvania, 2009","volume":"58","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2010.10.039_bib0140","series-title":"Current protocols in molecular biology","article-title":"Preparation of cell cultures and vaccinia virus stocks","author":"Earl","year":"1998"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0145","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/intimm\/5.6.647","article-title":"Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus","volume":"5","author":"Chen","year":"1993","journal-title":"Int Immunol"},{"issue":"August (16)","key":"10.1016\/j.vaccine.2010.10.039_bib0150","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2010.10.039_bib0155","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.4049\/jimmunol.172.10.6265","article-title":"Cellular and humoral immunity against vaccinia virus infection of mice","volume":"172","author":"Xu","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.10.039_bib0160","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2010.10.039_bib0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/icb.1968.20","article-title":"A study of the possible basis of age-dependent resistance of mice to poxvirus diseases","volume":"46","author":"Subrahmanyan","year":"1968","journal-title":"Aust J Exp Biol Med Sci"},{"issue":"July (13)","key":"10.1016\/j.vaccine.2010.10.039_bib0170","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/JVI.00427-06","article-title":"Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB\/c mice","volume":"80","author":"Tscharke","year":"2006","journal-title":"J Virol"},{"issue":"November (45)","key":"10.1016\/j.vaccine.2010.10.039_bib0175","first-page":"7743","article-title":"Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice","volume":"25","author":"Melamed","year":"2007","journal-title":"Vaccine"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2010.10.039_bib0180","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1086\/381101","article-title":"Lack of vaccinia viremia after smallpox vaccination","volume":"38","author":"Cummings","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"April (138)","key":"10.1016\/j.vaccine.2010.10.039_bib0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/adc.28.138.110","article-title":"Fatal generalized vaccinia with failure of antibody production and absence of serum gamma globulin","volume":"28","author":"Keidan","year":"1953","journal-title":"Arch Dis Child"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0190","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/JVI.00984-08","article-title":"Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox","volume":"83","author":"Wei","year":"2009","journal-title":"J Virol"},{"issue":"Pt 3","key":"10.1016\/j.vaccine.2010.10.039_bib0195","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1099\/0022-1317-66-3-643","article-title":"Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo","volume":"66","author":"Payne","year":"1985","journal-title":"J Gen Virol"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0200","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/oxfordjournals.aje.a121360","article-title":"The nature of the immune state produced by inactivated vaccinia virus in rabbits","volume":"94","author":"Boulter","year":"1971","journal-title":"Am J Epidemiol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2010.10.039_bib0205","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","article-title":"An investigation of the therapeutic value of vaccinia- immune IgG in a mouse pneumonia model","volume":"86","author":"Law","year":"2005","journal-title":"J Gen Virol"},{"issue":"August (Pt 8)","key":"10.1016\/j.vaccine.2010.10.039_bib0210","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1099\/0022-1317-78-8-2041","article-title":"Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation","volume":"78","author":"Vanderplasschen","year":"1997","journal-title":"J Gen Virol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.10.039_bib0215","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines","volume":"28","author":"Miller","year":"2008","journal-title":"Immunity"},{"issue":"November (49)","key":"10.1016\/j.vaccine.2010.10.039_bib0220","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1016\/j.vaccine.2007.09.050","article-title":"Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate","volume":"25","author":"Ferrier-Rembert","year":"2007","journal-title":"Vaccine"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2010.10.039_bib0225","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1128\/JVI.78.8.3811-3816.2004","article-title":"Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells","volume":"78","author":"Amara","year":"2004","journal-title":"J Virol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0230","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1084\/jem.20062363","article-title":"Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses","volume":"204","author":"Precopio","year":"2007","journal-title":"J Exp Med"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2010.10.039_bib0235","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.76.7.3329-3337.2002","article-title":"Recombinant vaccinia virus- induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope","volume":"76","author":"Harrington","year":"2002","journal-title":"J Virol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2010.10.039_bib0240","doi-asserted-by":"crossref","first-page":"8243","DOI":"10.4049\/jimmunol.179.12.8243","article-title":"CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses","volume":"179","author":"Novy","year":"2007","journal-title":"J Immunol"},{"issue":"October","key":"10.1016\/j.vaccine.2010.10.039_bib0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-065X.1997.tb01011.x","article-title":"Cytokines and immunity to viral infections","volume":"159","author":"Ramshaw","year":"1997","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2010.10.039_bib0250","unstructured":"Centers for Disease Control and Prevention. Smallpox Response Plan and Guidelines (Version 3.0). http:\/\/www.bt.cdc.gov\/agent\/smallpox\/response-plan\/index.asp; 2003."},{"issue":"October (8)","key":"10.1016\/j.vaccine.2010.10.039_bib0255","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1586\/14760584.7.8.1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"Artenstein","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0260","first-page":"656","article-title":"Adverse events following smallpox vaccination with ACAM2000 in a military population","volume":"146","author":"Beachkofsky","year":"2010","journal-title":"Arch Dermatol"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2010.10.039_bib0265","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/JVI.01854-07","article-title":"Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge","volume":"82","author":"Berhanu","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.10.039_bib0270","unstructured":"Gilead. VISTIDE\u00ae (cidofovir injection). http:\/\/www.gilead.com\/pdf\/vistide.pdf; 1996."},{"issue":"August (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1542\/peds.18.2.177","article-title":"Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy","volume":"18","author":"Kempe","year":"1956","journal-title":"Pediatrics"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2010.10.039_bib0280","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1086\/378518","article-title":"Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques","volume":"188","author":"Edghill-Smith","year":"2003","journal-title":"J Infect Dis"},{"issue":"May","key":"10.1016\/j.vaccine.2010.10.039_bib0285","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0031-3955(16)30945-2","article-title":"Clinical investigation of patients with agammaglobulinemia and hypogammaglobulinemia","volume":"7","author":"Good","year":"1960","journal-title":"Pediatr Clin North Am"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2010.10.039_bib0290","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2010.10.039_bib0295","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0300","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nm.2078","article-title":"Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity","volume":"16","author":"Liu","year":"2010","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2010.10.039_bib0305","first-page":"307","article-title":"The minimum protective level of antibodies in smallpox","volume":"52","author":"Sarkar","year":"1975","journal-title":"Bull World Health Organ"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2010.10.039_bib0310","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1972.21.214","article-title":"A prospective study of serum antibody and protection against smallpox","volume":"21","author":"Mack","year":"1972","journal-title":"Am J Trop Med Hyg"},{"issue":"October (Suppl 2)","key":"10.1016\/j.vaccine.2010.10.039_bib0315","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1201-9712(04)00134-1","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2014a second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int J Infect Dis"},{"issue":"November (22)","key":"10.1016\/j.vaccine.2010.10.039_bib0320","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2010.10.039_bib0325","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ni762","article-title":"Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo","volume":"3","author":"Norbury","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2010.10.039_bib0330","unstructured":"Military Vaccine (MILVAX) Agency. Smallpox vaccination saftey summary: DoD smallpox vaccination program. http:\/\/smallpox.mil\/event\/spsafetysum.asp; 2007."},{"key":"10.1016\/j.vaccine.2010.10.039_bib0335","unstructured":"Military Vaccine (MILVAX) Agency. Smallpox Vaccination Program www.smallpox.army.mil\/documents\/Smallpox_QA.pdf; 2008."},{"issue":"July (25)","key":"10.1016\/j.vaccine.2010.10.039_bib0340","first-page":"773","article-title":"Vaccinia virus infection after sexual contact with a military smallpox vaccinee\u2014washington, 2010","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2010.10.039_bib0345","unstructured":"U.S. Department of Defense. Panels find vaccines may relate to reservist's illness, death. http:\/\/www.defenselink.mil\/releases\/release.aspx?releaseid=5799; 2003."},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0350","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1084\/jem.20082835","article-title":"Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum","volume":"206","author":"Kawakami","year":"2009","journal-title":"J Exp Med"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.10.039_bib0355","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","article-title":"Efficacy of cidofovir in a murine model of disseminated progressive vaccinia","volume":"48","author":"Neyts","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10015094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10015094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T02:10:23Z","timestamp":1685844623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10015094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0264410X10015094"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.10.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}